MedTrace Logo

Leader - Evaluation of Endotak Reliance

NCT00180349 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 904

Last updated 2017-04-14

No results posted yet for this study

Summary

The objective of this study is to demonstrate the efficacy of the ENDOTAK® RELIANCE™ defibrillation leads connected to a defibrillator or a cardiac resynchronization defibrillator from implant until 12 months.

Conditions

  • Ventricular Tachycardia
  • Ventricular Fibrillation

Interventions

DEVICE

Endotak Reliance

Endotak Reliance is a defibrillation lead delivering pacing and defibrillation therapy to the ventricle as needed.

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Nicolas Sadoul, MD · CHU Brabois, Nancy

  • Arnaud Lazarus, MD · Clinique Bizet, Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00180349 on ClinicalTrials.gov